Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our mission is to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Dr. Patrick Serruys,
Mr Roger Hall,
Presenter: Roger Hall | see Discussant report
List of Authors: Akhil Kapur, Dr Andreas Baumbach (UK), Dr Kevin Beatt (UK), Dr Peter Crean (ROI), Dr Adam De Belder (UK), Dr Farzin Fath-Ordoubadi (UK), Prof Marcus Flather (UK), Professor Roger Hall (UK), Dr Iqbal Malik (UK)
Objectives:The purpose of this study was to compare the safety and efficacy of percutaneous coronary intervention (PCI) with stenting against coronary artery bypass grafting (CABG) in patients with diabetes and symptomatic multivessel coronary artery disease.
Background: CABG is the established method of revascularization in patients with diabetes and multivessel coronary disease, but with advances in PCI, there is uncertainty whether CABG remains the preferred method of revascularization.
Methods:The primary outcome was a composite of all-cause mortality, myocardial infarction (MI), and stroke, and the main secondary outcome included the addition of repeat revascularization to the primary outcome events. A total of 510 diabetic patients with multivessel or complex single-vessel coronary disease from 24 centers were randomized to PCI plus stenting (and routine abciximab) or CABG. The primary comparison used a noninferiority method with the upper boundary of the 95% confidence interval (CI) not to exceed 1.3 to declare PCI noninferior. Bare-metal stents were used initially, but a switch to Cypher (sirolimus drug-eluting) stents (Cordis, Johnson & Johnson, Bridgewater, New Jersey) was made when these became available.
Results: At 5.1 median years of follow-up, the composite rate of death, MI, and stroke was 20.5% in the CABG group and 26.6% in the PCI group (hazard ratio [HR]: 1.34, 95% confidence interval [CI] 0.94 to 1.93; p=0.11), all-cause mortality rates were 12.6% and 14% respectively (HR: 1.17, 95% CI 0.73 to 1.87; p=0.53), and the rates of death, MI, stroke, or repeat revascularization 26% and 37.5% (HR: 1.56, 95% CI 1.14 to 2.14; p=0.005), respectively. Stroke rate was numerically higher in the CABG group (4.3% vs 3.1%, HR: 0.72, 95% CI 0.29 to 1.79; p=0.48), and MI rate significantly higher in the PCI group (6.3% CABG vs 14% PCI, HR: 2.26, 95% CI 1.25 to 4.08; p=0.007).
Conclusions: The CARDia (Coronary Artery Revascularization in Diabetes) trial is the first randomized trial of coronary revascularization in diabetic patients. The 5-year results did not confirm that PCI is non-inferior to CABG. However, the CARDia trial did show that multivessel PCI is feasible in patients with diabetes. Data from other trials will provide a more precise comparison of the efficacy of these 2 revascularization strategies.
What is new?Previous reports of much higher mortality for PCI at 5 yrs not confirmed and mortality is very similar for the two treatments. CABG remains the preferred method of revascularisation unless there are clinical features that make PCI preferable.
Discussant: Patrick Serruys | see Presenter abstract
710009 - 710010
Clinical Trial & Registry Update II: Updates on Heart Failure and Coronary Artery Disease
© 2017 European Society of Cardiology. All rights reserved